Your browser doesn't support javascript.
loading
Familial male-limited precocious puberty due to an activating mutation of the LHCGR: a case report and literature review.
Ha, Jihyun; Choi, Yunha; Jung, Mo Kyung; Yoo, Eun-Gyong; Yoo, Han-Wook.
Afiliação
  • Ha J; Department of Pediatrics, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
  • Choi Y; Department of Pediatrics, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
  • Jung MK; Department of Pediatrics, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
  • Yoo EG; Department of Pediatrics, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
  • Yoo HW; Department of Pediatrics, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
Ann Pediatr Endocrinol Metab ; 29(1): 60-66, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38461807
ABSTRACT
Familial male-limited precocious puberty (FMPP) is a rare form of gonadotropin-independent precocious puberty that is caused by an activating mutation of the LHCGR gene. Herein, we report a case of FMPP with a mutation of the LHCGR gene in a Korean boy with familial history of precocious puberty through 3 generations. A 16-month-old boy presented with signs of precocious puberty, including pubic hair, acne, and increased growth velocity. The patient's grandfather and father had a history of precocious puberty and profound short stature. On physical examination, the patient had prepubertal testes with pubic hair development appropriate for Tanner stage II. The stretched penile length was 7 cm (>2 standard deviation score), and observed bone age was that of a 4-year-old boy. Laboratory findings showed high serum testosterone (5.74 ng/mL [appropriate for Tanner IV-V]; normal range, <0.05 ng/mL) with suppressed luteinizing hormone (<0.07 mIU/mL) and normal serum level of follicular stimulating hormone (0.56 mIU/mL; normal range, 0.38-1.11 mIU/mL). Genetic testing revealed a pathogenic variant of LHCGR (c.1730 C>T (p.Thr577Ileu)), confirming FMPP. Bicalutamide and anastrozole were administered, and pubertal progression was sufficiently suppressed without any specific side effects. To our knowledge, this is the first case of genetically confirmed FMPP in Korea.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Pediatr Endocrinol Metab Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Pediatr Endocrinol Metab Ano de publicação: 2024 Tipo de documento: Article